Scarica l'app Stockscreener
0.6612
2.69%
0.0173
Dopo l'orario di chiusura:
.65
-0.0112
-1.69%
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - Investing.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Canada
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - biobuzz.io
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - Stock Titan
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - marketscreener.com
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics, Inc. SEC Filing (Aug 17, 2026) | OTLK NT 10-Q - Stock Titan
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear - simplywall.st
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):